Hycamtin (topotecan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	☐ URGENT
MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	
	WEIGHT (LB/KG): ALLERGIES:
FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP	PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLIC	CABLE):
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _	
PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	L
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:
MEDICATION OR MEDICAL DISPENSING INFORMAT	TION
MEDICATION NAME:	
DOSE/STRENGTH: FREQUENCY:	LENGTH OF QUANTITY: THERAPY/REFILLS:
NEW THERAPY RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:
DURATION OF THERAPY (SPECIFIC DATES):	

Continued on next page.



Hycamtin (topotecan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHE	ER MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Relapsed small cell lung cancer		
□ Other DiagnosisICD-10	Code(s):	
3. REQUIRED CLINICAL INFORMATION	N: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Clinical Information:		
Has the patient had a complete or pa	rtial response to first-line chemotherapy	/? □ Yes □ No
Is the nations at least 45 days out (an	d not greater than 180 days out) from th	as and of their first line
chemotherapy?* \square Yes \square No	a not greater than 180 days out, from th	ie end of their first-fine
	ı (i.e., chart notes) supporting this inform	nation.
•		
Is the patient a candidate for I.V. adn	ninistration of topotecan? ☐ Yes ☐ No	
Reauthorization:		
If this is a reauthorization request, ar	<u> </u>	
Has the patient had a positive tumor	response to therapy? ☐ Yes ☐ No	
Are there any other comments diagr	noses, symptoms, medications tried or fa	siled and/or any other information the
physician feels is important to this re		med, and/or any other information the
,,		
	re covered on all plans. This request may	be denied unless all required
information is received.	n provided is true and assurate to the he	est of my knowledge. Lunderstand that
	on provided is true and accurate to the be up or its designees may perform a routine	,
	curacy of the information reported on the	·
, ,	•	
Prescriber Signature or Electronic I.D		Date:
	companying this transmission contain confidential reby notified that any disclosure, copying, distribu	
	u have received this information in error, please no	

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.